INTRODUCTION 95
In 2014, there were an estimated 9.6 million new cases of tuberculosis (TB) globally, including 1 million 96 children. TB is the leading cause of mortality and morbidity in people living with the human 97 immunodeficiency virus (HIV), and in 2015 TB caused 55,000 deaths in HIV-infected children, comprising 98 40% of all TB-related childhood deaths. 1 The highest burden of coinfection occurs in sub-Saharan Africa, 99 with 3-47% of HIV-infected children reported to have TB in different cohorts.
2-5 100
Although antiretroviral therapy (ART) substantially reduces TB incidence in HIV-infected children, 2,4-7 it 101 may not completely restore functional immune response against the disease and other environmental 102 TB risk factors remain in this population. In the ART era TB incidence remains higher in HIV-infected 103 children than in non-infected children or the general paediatric population, regardless of setting. 3, 5, 8, 9 TB 104 diagnosis is difficult in children with HIV infection due to overlapping clinical presentations and frequent 105 HIV-related respiratory comorbidities. Furthermore, confirmation of TB is challenging because of the 106 paucibacillary nature of disease and difficulties in obtaining specimens in children; diagnosis is therefore 107 often presumptive, complicating effective management. 108
Successful anti-tuberculosis treatment (ATT) outcomes in HIV-infected children vary across settings, 109 ranging from 69% to 88%.
2,10-11 Concomitant ATT may compromise HIV virological control due to drug 110 interactions between rifamycins and some antiretrovirals, leading to longer time to viral load (VL) 111 suppression and higher resistance mutation rates. 
MATERIALS AND METHODS 118
The Paediatric TB-HIV Observational Study was established as part of EuroCoord, an EU funded network 119 of excellence on enhancing clinical and epidemiological HIV research in Europe through cohort 120 collaboration (http://www.eurocoord.net). Of 28 multicentre cohorts and clinical sites approached, 15 121 cohorts/sites collaborating within PENTA (http://penta-id.org/hiv.html) participated (Fig 1) . HIV-infected 122 children (aged <16 years) diagnosed with TB within a 3-year period, from 1 January 2011 to 31 123
December 2013, at the time of TB diagnosis were included. Patients were followed-up for two years 124 from TB diagnosis. 125
Anonymised patient data were collected on standardised forms by collaborating physicians. Mycobacterium tuberculosis complex using culture and/or molecular tests or identification of acid-fast 137 bacilli by microscopy in the absence of positive cultures for non-tuberculous mycobacteria. 138
Immunological evidence of M.tuberculosis infection included positive tuberculin skin test (TST) and/or 139 interferon-gamma release assays (IGRA). Clinical forms of TB were categorised into pulmonary, extra-140 pulmonary, and both pulmonary and extrapulmonary; TB disease was classified as severe and non-141 severe. 16 We adapted the consensus adult TB-immune reconstitution inflammatory syndrome (IRIS) case 142 definition for paediatric use.
17 TB-IRIS was defined as a new TB diagnosis or worsening of TB without 143 alternative explanation following initiation, reintroduction or change in ART and evidence of either (1) a 144 more than two-fold rise in CD4 count, (2) a reduction in VL of >0.5 log10, or (3) weight gain or other signs 145 of clinical improvement in response to ART. ATT outcomes were classified as cured, treatment 146 completed, treatment not completed, TB recurrence, TB-related death, TB-unrelated death, and 147 outcome not known. Time of viral suppression was defined at the midpoint of the first VL≤400 copies/ml 148 and the preceding measurement. Height-for-age and body mass index (BMI) Z-scores were used to 149 assess stunting and wasting, respectively. 
Statistical analysis 152
TB incidence per 100,000 PY was calculated as the reported number of incident TB cases in the 153 participating cohorts in the three year study period divided by the number of children at risk (estimated 154 as 3*number of children under follow-up at the end of 2013 Most (89%) children were symptomatic at presentation, with cough, fever and weight loss in 208 respectively 61%, 54% and 30%; 17% (n=18) of the 104 children had symptoms for >3 months. The most 209 common clinical presentation was pulmonary TB alone, and overall one-third of children had severe 210 forms of TB. There were no geographic differences in the proportion with severe TB (p=0.4091) and no 211 age differences in children with severe and non-severe TB (median age for severe and non-severe TB 7. In this study we evaluated TB in HIV-infected children followed in cohorts/clinical sites in high-and 245 middle-income countries. Estimated TB incidence rates indicate that incident TB in this population is 246 substantially higher than in the general population in the same countries. 1, 19, 20 The younger age of the 247 TB cases in Eastern Europe may reflect the more recent HIV epidemic there. Children with TB living in 248
Thailand or Brazil tended to have more severe HIV disease than those in Europe at TB diagnosis, possibly 249 due to suboptimal access to care for populations most-at-risk of HIV and TB. 250
For most TB cases in our study, the HIV diagnosis came first. IPT in known HIV-infected children was 251 underutilised (reported in only 23% children), and represents a missed opportunity for TB prevention. 252
IPT was effective in preventing TB in HIV-infected children in sub-Saharan Africa, 3, 21, 22 and is also an 253 effective adjunct to early ART for TB prevention in adults 23 , however, its role in unexposed children has 254 been debated. Our study highlights different management practices in paediatric TB across the regions, including more 276 SM use and suboptimal use of second-line drugs in Eastern Europe. SM is injected intramuscularly due 277 to poor oral absorption, has high toxicity and limited additional efficacy when added to first-line TB 278 treatment and is therefore not recommended. 34 Use of less than three second-line drugs in high MDR-TB 279 burden settings also raises concern as it provides suboptimal activity of the empiric ATT regimen 35 12,14 Good HIV outcomes 289 were previously reported for efavirenz (EFV) based ART. 13, 35 Although only a quarter of our cases 290 received EFV-based ART, the overall rate of virologically non-suppressed children was less than 10%. 291
Favourable outcomes were achieved in 92% of children, slightly higher than the 69-88% reported 292
elsewhere.
2,10,11 Previous acquired immune-deficiency syndrome (AIDS) diagnosis, not being virologically 293 supressed at TB diagnosis, and region (Brazil) were associated with unfavourable TB outcomes. 294
However as small numbers precluded adjusted analyses, these results should be interpreted with 295 caution as they are subject to confounding (e.g. children from Brazil were older and were more likely to 296 have a previous AIDS diagnosis than other children). The proportion of TB-related deaths (1.6%) is 297 relatively low compared to 3.3-11.7% in the literature.
2,4,7,10,11 This may reflect the health status of our 298 cases with nearly half had no/mild immunodeficiency and less than a third had AIDS. 299
300
This study has a number of limitations, including an observational design, with inherent limitations such 301 as incomplete data and possible underreporting of cases. However, we distributed reminders to report 302 all children with suspected TB regardless of follow-up status. Over-diagnosis of TB was possible as most 303 of our cases were presumptive. Our incidence rates were estimated based on cohort/clinic size, and 304 should be interpreted with caution. Finally, as we did not have national coverage in each country, except 305 for the United Kingdom, the results may not be generalizable to the whole country as differences in HIV 306
and TB epidemiology and healthcare provision likely exist. 307 
